aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference
aTyr Pharma (Nasdaq: ATYR) announced that Sanjay S. Shukla, M.D., M.S., President and CEO, will present at the Piper Sandler 37th Annual Healthcare Conference in New York, December 2–4, 2025.
The presentation is scheduled for Tuesday, December 2, 2025 at 1:00 PM EST in a fireside chat format. Management will be available for one-on-one investor meetings for registered attendees. A live webcast will be available on the company’s Investor section and a replay will remain on the aTyr website for at least 90 days. For investor inquiries, contact investorrelations@atyrpharma.com.
aTyr Pharma (Nasdaq: ATYR) ha annunciato che Sanjay S. Shukla, M.D., M.S., Presidente e CEO, parteciperà come relatore al Piper Sandler 37th Annual Healthcare Conference a New York, dal 2 al 4 dicembre 2025.
La presentazione è prevista per martedì 2 dicembre 2025 alle 13:00 EST in formato chiacchierata alla lume di candela (fireside chat). Il management sarà disponibile per incontri individuali con gli investitori per i partecipanti registrati. Una trasmissione in diretta sarà disponibile nella sezione Investitori della società e una replica rimarrà sul sito di aTyr per almeno 90 giorni. Per richieste degli investitori, contattare investorrelations@atyrpharma.com.
aTyr Pharma (Nasdaq: ATYR) anunció que Sanjay S. Shukla, MD, MS, presidente y director ejecutivo, participará como ponente en la Piper Sandler 37th Annual Healthcare Conference en Nueva York, del 2 al 4 de diciembre de 2025.
La presentación está programada para el martes 2 de diciembre de 2025 a las 1:00 PM EST en formato charla junto a una chimenea. La dirección ejecutiva estará disponible para reuniones individuales con inversores para los asistentes registrados. Una transmisión en vivo estará disponible en la sección de Inversores de la empresa y una réplica quedará en el sitio de aTyr durante al menos 90 días. Para consultas de inversores, contacte a investorrelations@atyrpharma.com.
aTyr Pharma (Nasdaq: ATYR)는 Sanjay S. Shukla 박사, M.D., M.S., 사장 겸 최고경영자(CEO)가 뉴욕에서 2025년 12월 2일부터 4일까지 열리는 Piper Sandler 37th Annual Healthcare Conference에 발표할 것이라고 발표했습니다.
발표는 2025년 12월 2일 화요일 오후 1시(동부 표준시 EST)에 파이어사이드 챗 형식으로 진행될 예정입니다. 경영진은 등록된 참석자에 한해 1대1 투자자 면담을 위해 대기합니다. 회사의 투자자 섹션에서 라이브 웹캐스트를 이용할 수 있으며 재방송은 최소 90일 동안 aTyr 웹사이트에 게시됩니다. 투자자 문의는 investorrelations@atyrpharma.com으로 연락해 주십시오.
aTyr Pharma (Nasdaq: ATYR) a annoncé que Sanjay S. Shukla, M.D., M.S., président et directeur général, interviendra lors de la Piper Sandler 37th Annual Healthcare Conference à New York, du 2 au 4 décembre 2025.
La présentation est prévue pour le mardi 2 décembre 2025 à 13h00 EST sous forme de discussion informelle (fireside chat). La direction sera disponible pour des entretiens individuels avec les investisseurs pour les participants enregistrés. Une diffusion en direct sera disponible dans la section Investisseurs de l’entreprise et une rediffusion restera sur le site d’aTyr pendant au moins 90 jours. Pour toute demande des investisseurs, contactez investorrelations@atyrpharma.com.
aTyr Pharma (Nasdaq: ATYR) hat bekannt gegeben, dass Sanjay S. Shukla, M.D., M.S., Präsident und CEO, auf der Piper Sandler 37th Annual Healthcare Conference in New York vom 2. bis 4. Dezember 2025 auftreten wird.
Die Präsentation ist für Dienstag, der 2. Dezember 2025 um 13:00 Uhr EST vorgesehen, im Format eines Fireside Chats. Das Management steht registrierten Teilnehmern für One-on-One-Investorengespräche zur Verfügung. Eine Live-Webcast wird im Bereich Investor der Firma verfügbar sein und eine Wiederholung wird für mindestens 90 Tage auf der aTyr-Website verbleiben. Bei Investor-Anfragen kontaktieren Sie investorrelations@atyrpharma.com.
aTyr Pharma (Nasdaq: ATYR) أعلنت أن سانجاي S. شوكلا، دكتور في الطب، دكتور في العلوم، رئيس تنفيذي و CEO، سيقدم في Piper Sandler 37th Annual Healthcare Conference في نيويورك، من 2 إلى 4 ديسمبر 2025.
من المقرر أن تكون العرض التقديمي في الثلاثاء 2 ديسمبر 2025 الساعة 1:00 مساءً بتوقيت شرق الولايات المتحدة في صيغة محادثة بجلسة حوارية دافئة. ستتاح للإدارة فرص لقاءات فردية مع المستثمرين للحاضرين المسجلين. وسيكون هناك بث مباشر في قسم المستثمرين بالشركة وسيظل الإعادة على موقع aTyr على الأقل لمدة 90 يوماً. للاستفسارات الاستثمارية، تواصل مع investorrelations@atyrpharma.com.
- None.
- None.
SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Piper Sandler 37th Annual Healthcare Conference, which is scheduled to take place December 2 – 4, 2025, in New York, NY.
Details of the presentation appears below:
Conference: Piper Sandler 37th Annual Healthcare Conference
Date: Tuesday, December 2, 2025
Time: 1:00pm EST
Location: New York, NY
Format: Fireside Chat
In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. A webcast of the event will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the event, a replay of the presentation will be available on the aTyr website for at least 90 days. For more information, contact investorrelations@atyrpharma.com.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
| Contact: |
| Ashlee Dunston |
| Sr. Director, Investor Relations and Public Affairs |
| adunston@atyrpharma.com |
FAQ
When will aTyr Pharma (ATYR) present at the Piper Sandler 37th Annual Healthcare Conference?
Who will represent aTyr Pharma (ATYR) at the Piper Sandler conference?
How can investors watch the aTyr Pharma (ATYR) presentation if they can't attend?
Can investors request one-on-one meetings with aTyr Pharma (ATYR) management at the conference?
Where will the aTyr Pharma (ATYR) Piper Sandler conference presentation take place?
Who should investors contact for more information about aTyr Pharma (ATYR) investor events?
